IGC Pharma, Inc. (IGC) - Q2 2025 (Ended Sept 30, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024 (Q2 of Fiscal Year 2025). IGC Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, alongside a Life Sciences segment selling wellness products and a legacy Infrastructure segment. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $412,000 | $291,000 | $684,000 | $846,000 |
| Gross Profit | $198,000 | $174,000 | $361,000 | $429,000 |
| Gross Margin | 48% | 60% | 53% | 51% |
| Operating Loss | $(1,760,000) | $(2,491,000) | $(4,156,000) | $(4,630,000) |
| Net Loss | $(1,717,000) | $(2,451,000) | $(4,095,000) | $(4,526,000) |
| Cash & Equivalents | $1,546,000 (as of Sept 30, 2024) | |||
| Working Capital | $1,447,000 (as of Sept 30, 2024) | |||
| Long-Term Debt | $135,000 (EIDL Loan) |
Material Changes vs. Prior Period
- Revenue Growth (QoQ): Revenue increased 42% year-over-year for the quarter to $412,000, driven by white-label projects in the Life Sciences segment. However, YTD revenue decreased 19% due to the completion of an Infrastructure project in India.
- Expense Reduction: Operating expenses decreased significantly. SG&A expenses fell 25% QoQ and 11% YTD, while R&D expenses dropped 28% QoQ and 10% YTD, primarily due to optimized trial progression and reduced marketing spend.
- Loss Narrowing: Net loss improved by 30% for the quarter and 10% YTD compared to the prior year periods.
- Asset Liquidation: The company entered an agreement to sell land in Nagpur, India, for approximately $716,000 (net realizable value), having previously impaired the asset from $4.1 million to $720,000.
Guidance, Outlook, and Risks
- Clinical Progress: The lead candidate, IGC-AD1, is in an ongoing Phase 2 trial for agitation in Alzheimer's. Early results suggest a faster onset of action (2 weeks) compared to traditional antipsychotics (6-12 weeks). Over 1,000 doses have been administered with no dose-limiting adverse events.
- Pipeline Expansion: AI modeling identified molecule IGC-1A as a potential GLP-1 agonist, opening potential markets in weight loss and neurological disorders. Other assets (TGR-63, IGC-1C, IGC-M3, LMP) remain in preclinical stages.
- Liquidity & Capital: The company raised approximately $3.3 million in net proceeds from equity issuances in the first half of the fiscal year. A $12 million credit facility with O-Bank was extended in July 2024 with reduced fees. Management states current cash is sufficient for operations beyond 12 months.
- Risks: Significant risks include the failure of clinical trials, inability to secure regulatory approval (FDA), reliance on equity financing which may be dilutive, and the uncertainty of commercializing hemp-based products.
Investor Verification Checklist
- Cash Runway: Verify if the $1.55 million cash balance and $12M credit facility are sufficient to fund the Phase 2 trial completion and subsequent Phase 3 planning without immediate dilution.
- Revenue Sustainability: Confirm the durability of the Life Sciences white-label revenue stream, as the Infrastructure segment revenue has ceased.
- Land Sale Closing: Monitor the finalization of the $716,000 land sale in India to ensure the cash proceeds are realized as projected.
- Dilution Impact: Review the terms of recent share purchase agreements (e.g., with Moran Global Strategies) and the ATM facility to assess potential dilution to existing shareholders.
- Clinical Milestones: Track the enrollment and interim data readout for the IGC-AD1 Phase 2 trial, which is the primary value driver for the company.